EHA 2021 | INSIGHT-MM: real-world analysis of DOT with Rd-based regimens in R/R myeloma
Noemí Puig, MD, PhD, University Hospital Salamanca, Salamanca, Spain, discusses outcomes from the observational, global INSIGHT-MM study (NCT02761187) which has analysed data from 821 patients with relapsed/refractory (R/R) multiple myeloma from 15 countries in order to asses the duration of treatment (DOT) with lenalidomide-dexamethasone (Rd)-based regimens. Dr Puig gives an overview of the rationale for the study and summarizes the key findings. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Noemi Puig, MD, PhD, has received honoraria from Amgen, Celgene, Janssen, Takeda and The Binding Site; has participated in a consulting or advisory role for Amgen, Celgene, Janssen and Takeda; has participated in speakers’ bureau for Celgene; and has received research funding from Celgene, Janssen, Amgen and Takeda.
